Monistat 3 NDA approval
This article was originally published in The Tan Sheet
J&J Monistat 3 Combination Pack label changes "to include additional instructions for disposable vaginal suppository applicators" approved by FDA Jan. 9. Approval letter for supplemental NDA 20-670/S-011 also contains labeling recommendations for both reusable and disposable applicator forms, which should be implemented at the next printing, FDA says. Advised changes include revising "declaration of net quantity of contents to distinctly identify both products within the package," modifying product name to reflect USP name for miconazole nitrate vaginal suppositories and various minor changes to the "Drug Facts" panel to reflect the OTC labeling final rule, agency notes...
You may also be interested in...
From relatively little-known to high-flying, hotly pursued targets by global pharma players, Chinese domestically developed immuno-oncology drugs are ascending in both value and attractiveness, both inside China and far beyond.
The leadership of top Indian firms recounted at the IPA Forum how they got together on a joint 45-minute call daily in the early phase of the pandemic to collaborate and ensure uninterrupted supplies of medicines both in India and globally. The executives also shared views on telemedicine and digitalization trends at the event.
Medtech Insight spoke to attorney Greg Dadika about mass tort litigation, including industry trends, how to find the right law firm, and when it’s the right time to settle a suit. See what Dadika, an attorney at the law firm Greenberg Traurig LLP, said about it here.